Equities analysts predict that Strongbridge Biopharma plc (NASDAQ:SBBP) will post sales of $1.97 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Strongbridge Biopharma plc’s earnings, with the lowest sales estimate coming in at $1.20 million and the highest estimate coming in at $2.96 million. The company is scheduled to report its next quarterly earnings results on Friday, December 22nd.

According to Zacks, analysts expect that Strongbridge Biopharma plc will report full-year sales of $1.97 million for the current financial year, with estimates ranging from $4.64 million to $8.11 million. For the next financial year, analysts expect that the business will post sales of $13.87 million per share, with estimates ranging from $9.39 million to $21.40 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Strongbridge Biopharma plc.

Strongbridge Biopharma plc (NASDAQ:SBBP) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.34). Strongbridge Biopharma plc had a negative net margin of 1,974.56% and a negative return on equity of 499.51%. The business had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.84 million.

SBBP has been the topic of several recent research reports. Zacks Investment Research downgraded shares of Strongbridge Biopharma plc from a “hold” rating to a “sell” rating in a research report on Thursday, September 28th. ValuEngine downgraded shares of Strongbridge Biopharma plc from a “hold” rating to a “sell” rating in a research report on Monday. Finally, Oppenheimer Holdings, Inc. initiated coverage on shares of Strongbridge Biopharma plc in a research report on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. Strongbridge Biopharma plc presently has a consensus rating of “Hold” and an average target price of $11.94.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Strongbridge Biopharma plc (SBBP) Will Announce Quarterly Sales of $1.97 Million” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/06/brokerages-anticipate-strongbridge-biopharma-plc-sbbp-will-announce-quarterly-sales-of-1-97-million.html.

Strongbridge Biopharma plc (NASDAQ:SBBP) opened at 6.15 on Friday. The stock’s market capitalization is $217.31 million. Strongbridge Biopharma plc has a 1-year low of $2.00 and a 1-year high of $8.85. The company has a 50-day moving average of $6.82 and a 200-day moving average of $5.69.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SBBP. Broadfin Capital LLC raised its position in Strongbridge Biopharma plc by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock worth $14,163,000 after acquiring an additional 87,125 shares during the period. Schwab Charles Investment Management Inc. bought a new stake in shares of Strongbridge Biopharma plc during the 2nd quarter valued at $332,000. Rhumbline Advisers bought a new stake in shares of Strongbridge Biopharma plc during the 2nd quarter valued at $154,000. State of Wisconsin Investment Board bought a new stake in shares of Strongbridge Biopharma plc during the 2nd quarter valued at $114,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Strongbridge Biopharma plc during the 2nd quarter valued at $331,000. Institutional investors and hedge funds own 63.65% of the company’s stock.

About Strongbridge Biopharma plc

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma plc (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.